Chronic activation of FXR in transgenic mice caused perinatal toxicity and sensitized mice to cholesterol toxicity

Molecular Endocrinology

Volumn 29, Issue 4, 2015, Pages 571-582

  Cheng, Qiuqiong ^a,f   Inaba, Yuka ^a,f   Lu, Peipei ^a,f   Xu, Meishu ^a,f   He, Jinhan ^a,f   Zhao, Yueshui ^a,f   Guo, Grace L ^d,e,f   Kuruba, Ramalinga ^a,f   De La Vega, Rona ^b,f   Evans, Rhobert W ^b,f   Li, Song ^a,f   Xie, Wen ^a,c,f  

^a Center for Pharmacogenetics and Department of Pharmaceutical Sciences   (United States)

^b Health Services and Epidemiology   (United States)

^c Pharmacology and Chemical Biology   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e Department of Pharmacology and Toxicology ^*  (United States)

^f RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; BILE ACID; BILIRUBIN; CHOLESTEROL; CYCLINE; DOXYCYCLINE; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR INDUCIBLE IMMEDIATE EARLY RESPONSE PROTEIN 14; GAMMA TOCOPHEROL; PROTEIN; RETINOL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR; TWEAK RECEPTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE ACID SYNTHESIS; BILIRUBIN BLOOD LEVEL; BINDING SITE; BODY WEIGHT; CELL INFILTRATION; CELL PROLIFERATION; CHOLESTEROL DIET; CONTROLLED STUDY; FEMALE; GALLSTONE FORMATION; GEL MOBILITY SHIFT ASSAY; GENE CONTROL; GENE EXPRESSION; GROWTH RETARDATION; HEPATOMEGALY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; INTESTINE; INTESTINE FLORA; LETHALITY; LIVER; LIVER TOXICITY; MACROPHAGE; MALE; MICROARRAY ANALYSIS; MOUSE; NEUTROPHIL; NONHUMAN; NORTHERN BLOTTING; PERINATAL PERIOD; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; SURVIVAL RATE; TISSUE SPECIFICITY; TRANSGENE; TRANSIENT TRANSFECTION; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN BLOOD LEVEL; VITAMIN DEFICIENCY; VITAMIN SUPPLEMENTATION; WESTERN BLOTTING; ANIMAL; BLOOD; DRUG EFFECTS; GENETICS; LIPID DIET; LIVER DISEASE; METABOLISM; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

ANIMALS; BILE ACIDS AND SALTS; CHOLESTEROL; DIET, HIGH-FAT; INTESTINES; LIVER; LIVER DISEASES; MICE; MICE, TRANSGENIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; VITAMIN A; VITAMIN E;

EID: 84926369053     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2014-1337     Document Type: Article

References (44)

1. Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science. 1999;284(5418):1362–1365
2. Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science. 1999;284(5418): 1365–1368
3. Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell. 1999;3(5):543–553
4. Liu Y, Binz J, Numerick MJ, Dennis S, et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intraand extrahepatic cholestasis. J Clin Invest. 2003;112(11):1678–1687
5. Moschetta A, Bookout AL, Mangelsdorf DJ. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat Med. 2004;10(12):1352–1358
6. Lee FY, de Aguiar Vallim TQ, Chong HK, et al. Activation of the farnesoid X receptor provides protection against acetaminopheninduced hepatic toxicity. Mol Endocrinol. 2010;24(8):1626–1636
7. Duran-Sandoval D, Cariou B, Percevault F, et al. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem. 2005;280(33):29971–29979
8. Ma K, Saha PK, Chan L, Moore DD. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest. 2006;116(4): 1102–1109
9. Stayrook KR, Bramlett KS, Savkur RS, et al. Regulation of carbodoi hydrate metabolism by the farnesoid X receptor. Endocrinology. 2005;146(3):984–991
10. Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA. 2006;103(4):1006–1011
11. Yang F, Huang X, Yi T, Yen Y, Moore DD, Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 2007;67(3):863–867
12. Maran RR, Thomas A, Roth M, et al. Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J Pharmacol Exp Ther. 2009;328(2): 469–477
13. Kim I, Morimura K, Shah Y, Yang Q, Ward JM, Gonzalez FJ. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis. 2007;28(5):940–946
14. Huang W, Ma K, Zhang J, et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science. 2006;312(5771):233–236
15. Chen WD, Wang YD, Zhang L, et al. Farnesoid X receptor alleviates age-related proliferation defects in regenerating mouse livers by activating forkhead box m1b transcription. Hepatology. 2010; 51(3):953–962
16. Pellicciari R, Fiorucci S, Camaioni E, et al. 6a-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002;45(17): 3569–3572
17. Saini SP, Sonoda J, Xu L, et al. A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification. Mol Pharmacol. 2004;65(2):292–300
18. Lee JH, Wada T, Febbraio M, et al. A novel role for the dioxin receptor in fatty acid metabolism and hepatic steatosis. Gastroenterology. 2010;139(2):653–663
19. Chandler CE, Wilder DE, Pettini JL, et al. CP-346086: An MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res. 2003;44(10):1887–1901
20. Xie W, Barwick JL, Downes M, et al. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature. 2000; 406(6794):435–439
21. Cheng Q, Aleksunes LM, Manautou JE, et al. Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity. Mol Pharm. 2008;5(1):77–91
22. Wada T, Kang HS, Angers M, et al. Identification of oxysterol 7a-hydroxylase (Cyp7b1) as a novel retinoid-related orphan receptor a (RORa) (NR1F1) target gene and a functional cross-talk between RORa and liver X receptor (NR1H3). Mol Pharmacol. 2008;73(3):891–899
23. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem. 2003;72:137–174
24. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005;2(4):217–225
25. Landrier JF, Eloranta JJ, Vavricka SR, Kullak-Ublick GA. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-a and -b genes. Am J Physiol Gastrointest Liver Physiol. 2006;290(3):G476–G485
26. Li H, Chen F, Shang Q, et al. FXR-activating ligands inhibit rabbit ASBT expression via FXR-SHP-FTF cascade. Am J Physiol Gastrointest Liver Physiol. 2005;288(1):G60–G66
27. Neimark E, Chen F, Li X, Shneider BL. Bile acid-induced negative feedback regulation of the human ileal bile acid transporter. Hepatology. 2004;40(1):149–156
28. Jakubowski A, Ambrose C, Parr M, et al. TWEAK induces liver progenitor cell proliferation. J Clin Invest. 2005;115(9):2330–2340
29. Itoh T, Kamiya Y, Okabe M, Tanaka M, Miyajima A. Inducible expression of Wnt genes during adult hepatic stem/progenitor cell response. FEBS Lett. 2009;583(4):777–781
30. Chicheportiche Y, Bourdon PR, Xu H, et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem. 1997;272(51):32401–32410
31. Hofmann AF. Bile acids: Trying to understand their chemistry and biology with the hope of helping patients. Hepatology. 2009;49(5): 1403–1418
32. Glantz A, Marschall HU, Lammert F, Mattsson LA. Intrahepatic cholestasis of pregnancy: A randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology. 2005; 42(6):1399–1405
33. Zhang Y, Yin L, Anderson J, et al. Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia. J Biol Chem. 2010;285(5):3035–3043
34. Hageman J, Herrema H, Groen AK, Kuipers F. A role of the bile salt receptor FXR in atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30(8):1519–1528
35. Gadaleta RM, van Erpecum KJ, Oldenburg B, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. 2011;60(4):463–472
36. Inagaki T, Moschetta A, Lee YK, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci USA. 2006;103(10):3920–3925
37. Wang YD, Chen WD, Wang M, Yu D, Forman BM, Huang W. Farnesoid X Receptor antagonizes nuclear factor KB in hepatic inflammatory response. Hepatology. 2008;48(5):1632–1643
38. Degirolamo C, Modica S, Vacca M, et al. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal- specific farnesoid X receptor reactivation. Hepatology. 2015;61(1):161–170
39. Ishibashi S, Schwarz M, Frykman PK, Herz J, Russell DW. Disruption of cholesterol 7a-hydroxylase gene in mice. I. Postnatal lethality reversed by bile acid and vitamin supplementation. J Biol Chem. 1996;271(30):18017–18023
40. Shea HC, Head DD, Setchell KD, Russell DW. Analysis of HSD3B7 knockout mice reveals that a 3a-hydroxyl stereochemistry is required for bile acid function. Proc Natl Acad Sci USA. 2007; 104(28):11526–11533
41. Wiley SR, Cassiano L, Lofton T, et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity. 2001;15(5):837–846
42. Feng SL, Guo Y, Factor VM, et al. The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas.AmJ Pathol. 2000;156(4):1253–1261
43. Brown SA, Richards CM, Hanscom HN, Feng SL, Winkles JA. The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-KB activation. Biochem J. 2003;371(pt 2):395–403
44. Tran NL, Mc Donough WS, Savitch BA, et al. Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-KB and correlate with poor patient outcome. Cancer Res. 2006;66(19):9535–9542.